TNF and inflammatory bowel disease: The overall rate of escalation to corticosteroid sparing medication for IBD with immunosuppressants or anti-TNF therapy or the combination was lower among the NS group (5.9%) compared to the patients who received corticosteroids for their IBD (41.8%, p<0.001) (Table 2).